Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hexamethylene bisacetamide-induced cutaneous vasculitis.

E K Rowinsky, W P McGuire, G J Anhalt

    Cancer Treatment Reports
    |May 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies.

    The British journal of dermatology·2019
    Same author

    Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330.

    Sarcoma·2012
    Same author

    Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.

    British journal of cancer·2011
    Same author

    Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer.

    British journal of cancer·2011
    Same author

    Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

    Clinical and experimental immunology·2010

    A patient developed nonthrombocytopenic purpura, a rare complication, during treatment with hexamethylene bisacetamide, an investigational tumor-differentiating agent. This case highlights a potential association between this antineoplastic therapy and leukocytoclastic vasculitis.

    Area of Science:

    • Oncology
    • Dermatology
    • Pathology

    Background:

    • Hexamethylene bisacetamide is an investigational tumor-differentiating agent currently in phase I clinical trials.
    • Antineoplastic agents are used in cancer therapy to inhibit tumor growth.

    Observation:

    • A patient undergoing treatment with hexamethylene bisacetamide developed nonthrombocytopenic purpura.
    • Purpura is characterized by the appearance of purple spots on the skin.

    Findings:

    • Histopathological examination revealed leukocytoclastic vasculitis.
    • Immunofluorescence studies showed deposition of Immunoglobulin A (IgA) and complement in the dermal vasculature.

    Implications:

    • Leukocytoclastic vasculitis is an extremely rare complication associated with antineoplastic agent therapy.

    Related Experiment Videos

  • This case report serves to alert clinicians to a potential adverse drug reaction associated with hexamethylene bisacetamide.